Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain

Amann, 2005, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer, Cancer Res, 65, 226, 10.1158/0008-5472.226.65.1 Helfrich, 2006, Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels, Clin Cancer Res, 12, 7117, 10.1158/1078-0432.CCR-06-0760 Pelloski, 2007, Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma, J Clin Oncol, 25, 2288, 10.1200/JCO.2006.08.0705 Sequist, 2008, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494 Yang, 2008, Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy, J Clin Oncol, 26, 2745, 10.1200/JCO.2007.15.6695 Bonner, 2010, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, Lancet Oncol, 11, 21, 10.1016/S1470-2045(09)70311-0 Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X Nayak, 2011, HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts, PLoS One, 6, e18198, 10.1371/journal.pone.0018198 Memon, 2009, Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts, Cancer Res, 69, 873, 10.1158/0008-5472.CAN-08-3118 Yeh, 2011, Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT, Proc Natl Acad Sci USA, 108, 1603, 10.1073/pnas.1010744108 Vasdev, 2011, Metabolic stability of 6, 7-dialkoxy-4-(2-, 3- and 4-[18 F]fluoroanilino) quinazolines, potential EGFR imaging probes, Bioorg Med Chem, 19, 2959, 10.1016/j.bmc.2011.03.032 Pisaneschi, 2010, Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation, Bioorg Med Chem, 18, 6634, 10.1016/j.bmc.2010.08.004 Samen, 2006, The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro, Nucl Med Biol, 33, 1005, 10.1016/j.nucmedbio.2006.09.008 Memon, 2011, PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer, Br J Cancer, 105, 1850, 10.1038/bjc.2011.493 Bahce, 2013, Development of [11C] erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status, Clin Cancer Res, 19, 183, 10.1158/1078-0432.CCR-12-0289 Lammertsma, 1996, Comparison of methods for analysis of clinical [11C]raclopride studies, J Cereb Blood Flow Metab, 16, 42, 10.1097/00004647-199601000-00005 Li, 2007, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes, Clin Cancer Res, 13, 3731, 10.1158/1078-0432.CCR-07-0088 Ling, 2006, Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers, Drug Metab Dispos, 34, 420, 10.1124/dmd.105.007765 Carey, 2006, Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, Cancer Res, 66, 8163, 10.1158/0008-5472.CAN-06-0453 Mulloy, 2007, Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib, Cancer Res, 67, 2325, 10.1158/0008-5472.CAN-06-4293 Rubin, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118 Mishani, 2005, High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors, J Med Chem, 48, 5337, 10.1021/jm0580196 Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc Natl Acad Sci USA, 105, 3041, 10.1073/pnas.0711741105 Wood, 2004, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells, Cancer Res, 64, 6652, 10.1158/0008-5472.CAN-04-1168 Okabe, 2007, Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification, Cancer Res, 67, 2046, 10.1158/0008-5472.CAN-06-3339